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Abstract. To reveal unknown and potentially important mechanisms of drug action, multi-
biomarker discovery approaches are increasingly used. Time-course relationships between drug
action and multi-biomarker proﬁles, however, are typically missing, while such relationships will
provide increased insight in the underlying body processes. The aim of this study was to
investigate the effect of the dopamine D2 antagonist remoxipride on the neuroendocrine system.
Different doses of remoxipride (0, 0.7, 5.2, or 14 mg/kg) were administered to rats by intravenous
infusion. Serial brain extracellular ﬂuid (brainECF) and plasma samples were collected and
analyzed for remoxipride pharmacokinetics (PK). Plasma samples were analyzed for concentra-
tions of the eight pituitary-related hormones as a function of time. A Mann–Whitney test was
used to identify the responding hormones, which were further analyzed by pharmacokinetic/
pharmacodynamic (PK/PD) modeling. A three-compartment PK model adequately described
remoxipride PK in plasma and brainECF. Not only plasma PRL, but also adrenocorticotrophic
hormone (ACTH) concentrations were increased, the latter especially at higher concentrations
of remoxipride. Brain-derived neurotropic factor (BDNF), follicle stimulating hormone (FSH),
growth hormone (GH), luteinizing hormone (LH), and thyroid stimulating hormones (TSH) did
not respond to remoxipride at the tested doses, while oxytocin (OXT)measurements were below
limit of quantiﬁcation. Precursor pool models were linked to brainECF remoxipride PK by Emax
drug effect models, which could accurately describe the PRL andACTH responses. To conclude,
this study shows how a multi-biomarker identiﬁcation approach combined with PK/PDmodeling
can reveal and quantify a neuroendocrine multi-biomarker response for single drug action.
KEY WORDS: blood–brain barrier; CNS; dose–response; hormones; pharmacokinetic/
pharmacodynamic models.
INTRODUCTION
To better understand pharmacological effects of central
nervous system (CNS) drugs on the whole biological system,
including the unknown mechanisms of action, a holistic
approach is key (1,2). Unfortunately, the focus of current
in vivo pharmacology is often on the known mechanism of
action only (3). Therefore, to obtain insight in multiple
system components, increasing efforts are made to show the
utility of a multi-biomarker discovery approach, both in
disease conditions and upon drug administration (3,4). With
that, the pathophysiological and pharmacological inﬂuences
are reﬂected by a multi-biomarker response.
Thereby, it is not enough to investigate dose versus
multi-biomarker response, because such relationships are not
unique, i.e., condition dependent. It is therefore important to
have insight into processes that govern drug distribution to
target sites, target binding kinetics, signal transduction, and
homeostatic feedback mechanisms. Such insight is obtained
by multilevel studies, i.e., measurement of different
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biomarker types in a time-dependent manner and advanced
pharmacokinetic/pharmacodynamic (PK/PD) modeling (5–7).
PK/PD modeling was successfully applied for the selec-
tive dopamine D2 antagonist remoxipride, both in human (8)
and rat (9), to predict the pharmacological response beyond
the tested conditions. The pharmacological response was
represented by prolactin (PRL), which is a well-known
biomarker for D2 antagonism (10,11). More speciﬁcally,
dopamine binding to the D2 receptor inhibits the prolactin
release from the pituitary into plasma, and therefore, D2
antagonism induces its release (10). Movin-Osswald and
Hammarlund-Udenaes (1995) developed a PK/PD model to
describe the PK of remoxipride in plasma in conjunction to its
effect on the PRL kinetics (synthesis, release, and elimina-
tion) in human subjects, to successfully predict the PRL
response after different and repeated doses. Then, in our lab,
Stevens et al. (2012) developed a translational PK/PD model
for remoxipride effects on PRL plasma concentrations in rats,
using data on brain extracellular ﬂuid (brainECF) concentra-
tions that could be identiﬁed as target site concentrations.
With that, they successfully predicted the human PK/PD data
of remoxipride and PRL of Movin-Osswald and
Hammarlund-Udenaes (1995). This indicated that plasma
PRL is a translatable biomarker of D2 antagonism.
So far, D2 antagonism was only reﬂected by a single
hormone, PRL. This hormone is part of the neuroendocrine
system, which consists of the hypothalamus, the pituitary, and
peripheral hormone glands (e.g., adrenal gland), containing a
variety of hormones. The neuroendocrine hormones are
highly regulated through feedback mechanisms of single
hormones on their own secretion or that of others, both in a
direct or an indirect manner. PRL and oxytocin (OXT), for
example, interact through a positive feedback loop in female
rats (12). Through the neuroendocrine system, the brain
controls the plasma hormone levels in response to neurolog-
ical stimuli. Thus, from a pharmacological perspective, a
change in plasma hormone concentration may reﬂect a
central drug action. This provides the unique opportunity to
study central pharmacology on plasma hormone concentra-
tions, overcoming the ethical and technical hurdles of taking
samples from the human brain. Plasma hormones are
released from the pituitary, which consists of the anterior
lobe (AL), the intermediate lobe (IL), and the posterior lobe
(PL). Dopaminergic neurons from the hypothalamus are
involved in regulating all these parts of the pituitary (13).
Release of hormones (e.g., PRL) that are stored in the AL
may be regulated by dopamine that is secreted from
tuberoinfundibular dopaminergic (TIDA) neurons into the
portal vein. Hormones from the IL and the PL (e.g., OXT)
are directly released, possibly from tuberohypothalamic
dopaminergic (THDA) neurons that project into the pitui-
tary. This tight connection between the dopaminergic and the
neuroendocrine system inspired us to use the neuroendocrine
system as a source for multi-biomarker discovery of dopami-
nergic agents.
Indeed, next to the dopamine-PRL connection, other
interactions between the dopaminergic system and neuroen-
docrine hormones have also been reported. For example, the
dopamine agonist bromocriptine is used to treat hypersecre-
tion of adrenocorticotrophic hormone (ACTH) in Nelson’s
disease (14) as well as hypersecretion of growth hormone
(GH) in acromegaly (15). Moreover, dopamine was found
to inhibit secretion of GH from human pituitary cells (16),
and dopamine D2 receptors have been identiﬁed on
thyroid stimulating hormone (TSH) adenoma’s (17).
Furthermore, stimulation of the D2 receptor leads to
suppression of the luteinizing hormone (LH) by induction
of the second messenger pituitary adenylate cyclase-
activating polypeptide (PACAP) in gonadotrophs (18).
Therefore, to understand whether these interactions be-
tween the dopaminergic and neuroendocrine system are
relevant to dopamine D2 antagonists in vivo, it seems of
interest to investigate their broader neuroendocrine re-
sponses in a well-controlled animal study.
In this study, we applied a multi-biomarker discovery
approach to investigate the neuroendocrine response to
remoxipride in rats. Serial sampling of brainECF and blood
was performed to determine the remoxipride PK in plasma
and brain, following the procedures as earlier described (19).
Blood samples were also analyzed for ACTH, brain-derived
neurotropic factor (BDNF), follicle-stimulating hormone
(FSH), GH, LH, OXT, PRL, and TSH to obtain a neuroen-
docrine multi-biomarker. We combined this approach with
PK/PD modeling to gain a comprehensive understanding of
the PK/PD relation between remoxipride and the neuroen-
docrine system.
METHODS
Animals
All animal experiments were performed in accordance
with the Dutch Law of Animal Experimentation. The study
protocols (DEC14051/DEC13186) were approved by the
Animal Ethics Committee in Leiden. Male Wistar rats (n= 111,
264 ± 17 g), Charles River, The Netherlands) were housed in
groups for 6–9 days until surgery (Animal Facilities Gorlaeus
Laboratories, Leiden, The Netherlands), under standard
environmental conditions with ad libitum access to food
(Laboratory chow, Hope Farms, Woerden, The Netherlands)
and acidiﬁed water. Artiﬁcial daylight was provided from 7:30
AM to 7:30 PM.
Surgery
Surgery was performed following the procedures as
described earlier (19), with slight adaptations. In short,
animals were kept under 2% isoﬂurane anesthesia while they
underwent surgery. They received cannulas in the femoral
artery for serial blood sampling and femoral vein for drug
administration. A microdialysis guide (CMA 12 Elite PAES,
Schoonebeek, The Netherlands) was implanted in caudate-
putamen (AP −1.0; L 3.0; V −3.4) for serial brainECF
sampling. Twenty-four hours before the experiment, the
microdialysis guide was replaced by a probe (CMA 12 Elite
PAES, 4 mm polycarbonate membrane, cut-off 20 kDA,
Schoonebeek, The Netherlands). Between surgery and ex-
periments, the animals were kept individually in Makrolon
type 3 cages for 7 days to recover from surgery.
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Experiments
Table I provides an overview of the groups and number
of rats used (study numbers EW01 and WB02). All experi-
ments started between 8:00 AM and 8:30 AM, with rats
randomly assigned to receive 0, 0.7, 5.2, or 14 mg/kg
remoxipride by a 10-min i.v. infusion at the start of
experiment (t = 0 min). Microdialysate perfusion buffer was
prepared as described earlier (20), and 60 min before the
experiment, the perfusion was started using a ﬂow rate of
1 μl/min until the end of experiment (see Table I for the
sampling times). Samples with a deviated ﬂow rate of >10%
were discarded. Microdialysate samples were stored at 4°C
during the experiment and at −80°C after the experiment
until analysis.
The extraction efﬁciency (in vivo recovery) of the
microdialysis probe was determined following an in vivo loss
experiment with 20, 100, 300, and 1000 ng/ml remoxipride.
The microdialysate concentrations were corrected for an
extraction efﬁciency of 11 ± 0.5% (mean ± SEM, n = 208).
Blood samples of 200 μl were taken at serial time points
(Table I) through the arterial cannula and collected in
heparin-coated eppendorf tubes. Animals received 200 μl
saline after each sampling. The samples were centrifuged
(1000 rpm, 10 min) for separation of plasma and were
subsequently stored at 4°C during the experiment and at
−20°C after the experiment until analysis.
Analytical Methods
Remoxipride in Plasma and Microdialysates. Remoxipride
concentrations in plasma and microdialysates were determined
following a previously published liquid chromatography tandem
mass spectrometry method (21) with small modiﬁcations to
improve the column lifetime. In short, formic acid instead of
triﬂuoro acetic acid was added to the solvents of on-line solid
phase extraction and liquid chromatography, while maintaining
the same performance in peak shape and resolution.
Plasma Hormones. The plasma hormone analysis was
performed with Bio-Plex® MAGPIX™ technology (Biorad
Laboratories, Veenendaal, The Netherlands). The hormones
ACTH, BDNF, FSH, GH, LH, PRL, and TSH were analyzed
using the commercially available multiplex assay for analysis
of pituitary hormones (RTPMAG-86K, Rat pituitary
magnetic bead panel, Merck Millipore, Darmstadt,
Germany). We followed the protocol provided by the
manufacturer, analyzing 10 μl of each sample in duplo. OXT
was analyzed using the commercially multiplex assay for
analysis of neuropeptides (RMNPMAG-83K, Rat/mouse
neuropeptide magnetic bead panel, Merck Millipore,
Darmstadt, Germany). We followed the protocol provided
by the manufacturer, analyzing 80 μl of each sample. Data
were acquainted, and concentrations were calculated using
the Bio-Plex® Data Pro™ software (Biorad Laboratories,
Veenendaal, The Netherlands). Data below lower or
above upper limit of quantiﬁcations were excluded,
which was below 9% for all hormones, except for OXT
for which most measurements were below limit of
quantiﬁcation (<3.84 pg/ml).
Identification of Responding Hormones for Further PK/PD
Analysis
To select responding hormones, the plasma hormone
concentration-time data were ﬁrst corrected for individual
hormone baseline concentrations as obtained before admin-
istration of remoxipride (t = −15 min). These data were used
to compare the experimental groups that received 5.2 or
14 mg/kg remoxipride with the placebo group (for baseline
hormone values during the experimental period). A Mann–
Whitney Wilcoxon non-parametric test was performed to
compare the baseline corrected concentrations at each time-
point for each hormone. Hormones that showed a signiﬁcant
difference (p < 0.05) for at least one time-point were selected
for further PK/PD analysis. All data analyses were performed
using R version 3.1.1.
PK/PD Modeling
NONMEM® version 7.3.0 with subroutine ADVAN13
was used to perform the PK/PD modeling on the remoxipride
concentrations in plasma and brainECF and the hormone
concentrations in plasma. In addition to data from the studies
described above, plasma and brainECF remoxipride concen-
trations were taken from a previously performed study in
which 4, 8, and 16 mg/kg remoxipride was administered by a
30-min i.v. infusion (Table I) (22). Criteria to develop the best
model were (i) signiﬁcant drop in objective function value
(OFV) calculated as −2loglikelihood ratio (>3.84, p < 0.05,
df = 1); (ii) parameter precision; (iii) goodness-of-ﬁt; (iv)
correlations; (v) condition number; (vi) shrinkage; (vii)
bootstrap; and (viii) visual predictive check (VPC). Further-
more, the PK/PD model for PRL was externally validated on
available data from Stevens et al. 2012 (9).
A sequential PK/PD modeling approach was applied, in
which the post hoc parameter estimates of the PK model were
used as input for the PK/PD model. For the PK model, data
were log-transformed, and an exponential error model was
found to best describe the residual variation of the data,
whereas for the PD models, a proportional error model was
selected.
RESULTS
Pharmacokinetics
A three-compartment model was identiﬁed to describe
the free remoxipride concentrations in plasma and brainECF
(Fig. 1, middle part). Inclusion of saturable remoxipride
clearance from plasma, described by Michaelis Menten
kinetics, was found to improve the description of the data
(dOFV −94, Fig. S1). This was particularly observed after low
and high remoxipride doses (Fig. S1). Furthermore, in
addition to passive blood–brain barrier (BBB) transport,
distribution from brainECF to plasma (dOFV −238) or
elimination from brainECF (dOFV −239) was found to
improve the model ﬁt. However, the model with distribution
from brainECF to plasma showed imprecise parameter
estimates (relative standard error (RSE) >1000%), and
therefore, the model with elimination from brainECF was
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selected. Parameter estimates showed good precision (RSE
<30%), and bootstrap showed accurate estimates (Table II).
Pharmacodynamics
Multi-Biomarker Discovery
As shown in Fig. 2a, not only plasma PRL but also
ACTH was found to respond to remoxipride treatment
(p < 0.05). The other hormones (BDNF, FSH, GH, LH, and
TSH) did not show a signiﬁcant response, while for oxytocin,
most measurements were below limit of quantiﬁcation.
Plasma PRL showed a response after both 5.2 and 14 mg/
kg, whereas ACTH only showed a response after 14 mg/kg
remoxipride. The response time proﬁles of plasma PRL were
similar for 5.2 and 14 mg/kg (Fig. 2b). Apparently, the
response maximum was already reached after 5.2 mg/kg.
Therefore, an additional study was performed in which
plasma PRL was measured after 0.7 mg/kg remoxipride
(EW01 study, Table I). The plasma PRL concentrations after
0.7 mg/kg remoxipride were not only lower, but also exhibited
a different longitudinal pattern. After 5.2 and 14 mg/kg, but
Fig. 1. Schematic overview of the ﬁnal PK/PD model describing the pharmacokinetics of remoxipride in
plasma and brain, as well as the pharmacodynamics for both PRL and ACTH. For explanation of the
abbreviations, the reader is referred to Tables IV and V
Table II. Remoxipride Pharmacokinetics (PK), Parameter Estimates, and Bootstrap Results for the PK Model Following Different Doses of
Remoxipride
Parameter Bootstrap (n = 50)
Parameter estimate RSE (%) Bootstrap mean CV (%)
Vmax,centr (μM/h) 5.9 25 5.9 32
km,centr (μM) 2.9 27 3.0 31
Vcentral (l) 0.14 8 0.13 10
QPL-periph (l/h) 2.6 8 2.6 9
Vperiph (l) 0.52 15 0.52 14
QPL-ECF,passive (l/h) 2.7 12 2.7 14
CLECF,el (l/h) 3.1 14 3.1 18
VbrainECF (l) 3.5 10 3.5 12
Residual error
Plasma 0.26 13 0.26 14
ECF 0.51 16 0.52 18
CL clearance, CV coefﬁcient of variation, km remoxipride concentration at half maximal clearance rate, Q passive distribution between
compartments, RSE relative standard error of estimate, Vmax maximal clearance rate, V volume of distribution
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not after 0.7 mg/kg, PRL showed a two-phasic decline
(Fig. 2b). For plasma ACTH, a quick response was observed
after 14 mg/kg, with ACTH levels back to baseline within 1 h.
No response was observed after 5.2 mg/kg (Fig. 2c).
PK/PD Model for PRL
For PRL, a pool model was identiﬁed linking brainECF
remoxipride to the PRL release, including a positive feedback of
PRL on its own synthesis (Fig. 1, upper part). First of all,
although PRL in the placebo group initially decreased and
subsequently increased (Fig. 2b), this trend was small relative to
the pharmacological response (∼3 vs ∼45 ng/ml). Therefore, a
steady baseline was assumed. Second, a turnover model
outperformed a pool model as indicated by a signiﬁcant
difference in the OFV (Table III, models A&B vs C&D, dOFV
>3.84, df = 1). However, inclusion of a positive feedback
component of plasma PRL (Fig. 1) on its own synthesis led to
a signiﬁcant improvement in comparisonwith both a poolmodel
and a turnover model (Table III, models A and C vs. E dOFV
>7.81, df = 3). Moreover, this model explained the two-phasic
decline (Fig. 3a), which was not possible without positive
feedback (Fig. 3b). The positive feedback parameters (Emax,pf,
EC50,pf) were ﬁxed to the values identiﬁed by Stevens et al.
(2012), assuming that these system-speciﬁc parameters are not
different between our earlier and more recent studies. Finally,
remoxipride in brainECF could better explain the PRL response
than remoxipride in plasma (Table III, model E vs F, dOFV>
3.84, df= 1). Parameter estimates were reasonably precise (RSE
<30%), and bootstrap evaluation showed good accuracy
(Table IV). The VPC showed a good agreement of the model
with the data (Fig. 3a). Themodel was found towell describe the
data from Stevens et al. 2012 (9), although the upper variation
was slightly overestimated (Fig. S2).
PK/PD Model for ACTH
Also, for ACTH, a pool model was identiﬁed, linking
remoxipride in brainECF to the release of ACTH into plasma
(Fig. 1, lower part). First of all, as indicated by a signiﬁcant
difference in the OFV, a pool model performed better than a
turnover model (Table II, model A&B vs C&D, dOFV >3.84,
df = 1). Second, although it was not possible to discriminate
between the model with brainECF remoxipride or plasma
remoxipride explaining the ACTH response (Table II, model
C vs D, dOFV <3.84, df = 1), the brainECF model (model C)
showed better parameter precision (28 vs 89%). Moreover,
the VPC showed better agreement, albeit a minor difference,
Fig. 2. Biomarker responses upon remoxipride treatment. a Heatmap showing the differential response of the different hormones after 5.2 and
14 mg/kg remoxipride. Red squares indicate a signiﬁcant difference compared to the control group that received saline (p < 0.05). b Different
response time curves for PRL and c ACTH after 0 (solid), 0.7 mg/kg (dashed), 5.2 (dot-dashed), or 14 mg/kg (dotted). Data are geometric mean
± geometric SD
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with the data for this model (Fig. 3c) as compared to model
D, with plasma remoxipride coupled to the response (Fig. 3d).
Finally, because ACTH only showed a response after a high
remoxipride dose, different drug effect models were com-
pared. An Emax-model showed an equal model ﬁt as a linear
slope model (Table III, model D vs E, dOFV <3.84, df = 1).
However, to have a beginning of a clue about the potency of
the ACTH response as compared to the PRL response, we
sticked to the Emax-model.
Since the degradation rate of ACTH (kdegr,acth) was
not identiﬁable on basis of the current data, it was ﬁxed
to a value of 24.5 h−1, as obtained in rats during the
ACTH decline after a stress response (23). Also, the
maximal drug effect parameter (Emax,rem,ACTH) was not
identiﬁable. However, because this parameter is a com-
posite of unknown underlying parameters, a literature
value was not available. Therefore, Emax,rem,ACTH was
chosen on basis of the sensitivity of the OFV to
Fig. 3. Prediction corrected visual predictive checks (n = 1000) for the remoxipride PK/PD model describing PRL after 0.7, 5.2, and 14 mg/kg
(top) and ACTH after 0, 5.2, and 14 mg/kg (bottom). The pool models with (a) and without (b) positive feedback are shown for the PRL
response. The models with ECF (c) and plasma (d) as target site of action are shown. Solid lines are the observed medians, and the shaded area
shows the 95% prediction interval around the simulated median. The extent to which this area captures the observed median is a measure of
correct model speciﬁcation. Ideally, at each point, 50% of the prediction interval is above the observed median, and 50% below. The large
prediction intervals in the third bin (see arrow) of ﬁgures c and d are explained by the fact that this bin contained only two observations
Table III. Steps in PK/PD Model Development for the Models Describing the PRL and ACTH Responses
Model Description OFV
PRL
A Turnover model with drug effect from remoxipride in brainECF on PRL release 1861
B Turnover model with drug effect from remoxipride in plasma on PRL release 1897
C Pool model with drug effect from remoxipride in brainECF on PRL release 1909
D Pool model with drug effect from remoxipride in plasma on PRL release 1916
E Pool model with drug effect from remoxipride in brainECF on PRL release + positive feedback
of PRL in its own synthesis [best model]
1848
ACTH
A Turnover model with drug effect (Emax model) from remoxipride in ECF on ACTH release 1957
B Turnover model with drug effect (Emax model) from remoxipride in plasma on ACTH release 1869
C Pool model with drug effect (Emax model) from remoxipride in ECF on ACTH release [best model] 1862
D Pool model with drug effect (Emax model) from remoxipride in plasma on ACTH release 1861
E Pool model with drug effect (linear slope model) from remoxipride in ECF on ACTH release 1860
Neuroendocrine Multi-Biomarker PK/PD of Remoxipride
Emax,rem,ACTH values of 1, 7.5, 10, 15, 20, and 100. Up till
a value of 10, the OFV dropped signiﬁcantly, but from a
value of 10 or higher, it showed no signiﬁcant difference
(dOFV <3.84). Therefore, Emax,rem,acth was ﬁxed to 10.
Here, it must be noted that, with changing Emax,rem,ACTH,
the EC50 changed almost linearly with the change in Emax,
while other parameters remained the same. Parameter
estimates of the best model (Table III, model C) showed
good precision (RSE <30%) and accuracy (Table V), and
the VPC showed good agreement between the model and
the data (Fig. 3c).
DISCUSSION
Our goal was to apply the multi-biomarker discovery
approach in a quantitative manner, with remoxipride as a
paradigm compound. To that end, hormones from the
neuroendocrine system were analyzed as a source for a
multi-biomarker to represent remoxipride effect. We showed
that not only PRL, but also ACTH acts as biomarker for
remoxipride pharmacology. Both these hormones are synthe-
sized in the so-called Btroph^ cells in the anterior pituitary,
from which they are continuously released. In our study, we
Table IV. Parameter Estimates and Bootstrap Results for the Remoxipride PK/PD Model Describing the PRL Response
Parameter Bootstrap (n = 100c)
Parameter estimate RSE (%) Bootstrap mean CV (%)
Emax,rem,prl 13.3 12 13.8 16
EC50,rem,prl (μM) 0.064 28 0.074 63
Bslprl (ng ml) 7.3 7 7.2 6
ksynth,prl (ng/ml/h) 41.7a 41.2
krel,prl (h−1) 0.35 12 0.36 18
kdegr,prl (h−1) 5.72b 5.72
Emax,pf,prl 3.47b 3.47
EC50,pf,prl (ng/ml) 12.4b 12.4
IIV
Bslprl 0.075 19 0.071 43
Residual error
Proportional 0.13 8 0.13 13
Bsl baseline, Emax maximal effect, CV coefﬁcient of variation, EC50 drug concentration at half maximal effect, IIV interindividual variability,
ksynth PRL synthesis rate in the lactotroph, krel PRL release rate from the lactotroph to plasma, kdegr degradation rate of PRL in plasma, pf
positive feedback, prl prolactin, rem remoxipride, RSE relative standard error of estimate
a ksynth was calculated from bslprl*kdegr,prl
bValues were obtained from literature
c 100 out of 100 bootstrap runs minimized successfully
Table V. Parameter Estimates and Bootstrap Results for the Remoxipride PK/PD Model Describing the ACTH Response
Parameter Bootstrap (n = 100d)
Parameter estimate RSE (%) Bootstrap mean CV (%)
Emax,rem,ACTH 10a 10
EC50,rem,ACTH (μM) 2.61 19 2.66 30
BslACTH (pg/ml) 24.6 8 24.6 5
ksynth,ACTH (pg/ml/h) 603b 603
krel,ACTH (h−1) 3.13 18 3.03 21
kdegr,ACTH (h−1) 24.5c 24.5
IIV
Bslprl 0.15 26 0.14 26
Residual error
Proportional 0.12 5 0.12 17
Bsl baseline, Emax maximal effect, CV coefﬁcient of variation, EC50 drug concentration at half maximal effect, IIV interindividual variability,
ksynth ACTH synthesis rate in the lactotroph, krel ACTH release rate from the lactotroph to plasma, kdegr degradation rate of ACTH in plasma,
pf positive feedback, prl ACTH, rem remoxipride, RSE relative standard error of estimate
a Parameter was not identiﬁable, and the value was chosen on basis of a sensitivity analysis. Informative over terminated
b ksynth was calculated from bslprl*kdegr,prl
cValue was obtained from literature
d 89 out of 100 bootstrap runs minimized successfully
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quantiﬁed the effect of remoxipride on the PRL and ACTH
release, as described by pool models, thereby gaining a
comprehensive understanding of remoxipride effect on the
neuroendocrine system. With that, we revealed the in vivo
concentration effect relation of brainECF remoxipride with
the hormones PRL and ACTH enabling the prediction of a
neuroendocrine response for other doses of remoxipride.
Pharmacokinetics
The brainECF concentrations were described by a three-
compartment PK model, which was developed ﬁrst to be
subsequently linked to the PK/PD model. This model
included drug elimination from the brain, conﬁrming a
previously developed PK model for remoxipride in rats (22).
Whether this represented remoxipride active transport from
brainECF to plasma, metabolism of remoxipride in the brain
or efﬂux of remoxipride from brainECF to cerebrospinal ﬂuid
(CSF) remains to be answered. No studies on remoxipride
being a substrate for efﬂux transporters have been reported,
to the knowledge of the authors. Interestingly, O-demethylase
activity has been observed in the rat brain (24), suggesting
that remoxipride metabolism in the brain may have occurred.
Furthermore, whereas Stevens et al. (2011) found linear
elimination from plasma, we identiﬁed saturable elimination,
described by Michaelis Menten kinetics. They applied a 30-
min infusion time, but we used a 10-min infusion time with
similar dose levels. This led to a 1.5 times higher maximal
plasma remoxipride concentrations in the current study,
making it more likely to observe saturation of metabolic
clearance. This is not surprising for remoxipride since in rats,
it is eliminated mainly through liver enzymatic processes of
demethylation and aromatic hydroxylation (25). However, in
humans, remoxipride is metabolized mainly via oxidation
(25), which may not be saturated at these concentrations.
Indeed, linear elimination was identiﬁed for remoxipride in
humans (26).
Pharmacodynamics
Dopaminergic control over the neuroendocrine system is
established via the tuberoinfundibular system, which consists
of TIDA, THDA, and periventricular hypothalamic dopami-
nergic (PHDA) neurons that connect the hypothalamus to
the pituitary (13). Therefore, we were interested in plasma
hormones that are released from the AL or the PL of the
pituitary as a reﬂection of central pharmacology of dopami-
nergic agents. Whereas PRL has been used as a biomarker
for central dopaminergic activity, exerted via the
tuberoinfundibular system, other neuroendocrine hormones
have not been used for this purpose. Surprisingly, despite the
potential to respond to dopaminergic perturbation as de-
scribed in the introduction, FSH, LH, GH, TSH, and BDNF
did not show a response to a single dose of remoxipride.
Thus, a D2 agonistic effect on these hormones or presence of
the D2 receptor on the secretory cells does not necessarily
imply a response to dopamine D2 antagonism. Also, within
4 h, we could not identify feedback regulation on these ﬁve
hormones by the two responding hormones. Unfortunately,
we were not able to measure OXT since its levels were lower
than the limit of quantiﬁcation, although it is likely that there
is an interaction between PRL and OXT (12). However, using
the multi-biomarker discovery approach on eight hormones,
we identiﬁed not only PRL, but also ACTH as a biomarker
for the D2 antagonist remoxipride.
PK/PD Model for PRL
To use PRL as a biomarker for prediction of the
response after a second remoxipride administration, it is
important to take into account underlying tolerance mecha-
nisms, either being the depletion of the lactotroph (pool
model) (8,9) or the stimulation of dopamine production by
PRL (agonist–antagonist interaction model) (27). Although
both models were able to account for the tolerance, only the
pool model could explicitly separate drug-speciﬁc and system-
speciﬁc parameters, enabling a proper translational step from
animal to human (9). The models seem to have similar
ﬂexibility to ﬁt the prolactin response after a D2 antagonist
challenge (27–29), and we also found a similar goodness-of-ﬁt
between the pool and the AAI models (AIC 1860 versus AIC
1844). In fact, to be able to discriminate between these
models, a continuous infusion with a D2 antagonist should be
applied. According to the pool model, the plasma PRL
concentrations will drop to baseline after the pool is empty.
Following the AAI model, the plasma PRL concentrations
will reach a higher steady state during the continuous
exposure. In this study, a pool model was found to describe
the prolactin response with brainECF remoxipride related to
the release of PRL. Furthermore, in agreement with Stevens
et al. (2012), the inclusion of a positive feedback of PRL on its
own synthesis signiﬁcantly improved the model with particu-
larly the two-phasic decline being better described (Fig. 3b).
This feedback mechanism works by increasing the Breﬁlling^
of the lactotrophs after release of PRL, possibly mediated
through stimulation of the PRL receptor on the lactotrophs
(9,10). Although the inclusion of the positive feedback
improved the data ﬁtting, caution must be taken with this
type of non-linear models. Bakshi et al. (2016) published a
tutorial on mathematical analysis of ordinary differential
equation (ODE) model behavior, showing that the pool
model with positive feedback has two steady states and
interesting stability behavior. This means that the model may
converge to one or the other steady state, depending on the speciﬁc
simulated trajectory, which could be affected by small changes in
dose or parameter values. Such behavior is not physiological, and
therefore caution should be taken when extrapolating to other
parameter regions or dosages. Still, the model proved powerful in
translating the PRL response from animal to human, which
provided inclusion of an if-condition that forced the prolactin
concentrations to remain above baseline prolactin concentrations
(9,30). Simulations with the current model including the if-
condition up to 10 h showed a convergence to the correct baseline.
Furthermore, dopamine D2 receptors inﬂuence PRL
release both at the level of the hypothalamus (TIDA
neurons) and the pituitary (lactotrophs) (10). Stimulation of
PRL release via D2 receptor antagonism at the TIDA
neurons would be mediated through reduced dopamine
release into the pituitary, whereas stimulation via the
lactotrophs would be mediated through antagonism directly
at the level of the pituitary. Reduced dopamine release via D2
antagonism at the TIDA neurons is driven by remoxipride in
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brainECF, whereas D2 antagonism at the lactotrophs is
driven by remoxipride in plasma, since the pituitary is
exposed to blood. With data on remoxipride both in plasma
and brainECF, we could compare these hypotheses to ﬁnd
that PRL release was driven by remoxipride in brainECF
(Table III). However, domperidone, another D2 antagonist
which hardly penetrates the brain, also stimulates prolactin
release (31). Indeed, drugs with limited brain penetration
exhibit a low ED50 of D2 receptor occupancy in the pituitary
as compared to that in the striatum, which correlated with the
ED50 of prolactin release (peripheral effect) as compared to
ED50 of apomorphine-induced stereotype behavior (central
effect) (32). This suggests that direct antagonism of pituitary
D2 receptors is responsible for the prolactin release. Unfor-
tunately, no such data exists on D2 antagonists with high
brain penetration (kp,uu >1) to investigate whether the
reduced dopamine release in the pituitary will become
dominant in stimulating the prolactin release. On basis of
temporal PK/PD analysis, we found brainECF remoxipride
driving the PRL response. Therefore, because remoxipride
highly penetrates the brain (kp,uu∼ 1), it is suggested that for
D2 antagonists with high brain penetration, the reduced
dopamine release into the pituitary becomes dominant in
driving the PRL response.
Finally, the estimated EC50,rem,prl of 64 nM was 2–4-fold
different from in vitro binding potencies of 113 nM (33) and
240 nM (34) for remoxipride on striatal D2 receptors measured
in rat brain homogenate, but comparable to the EC50 of 80 nM
found for the previously developed pool model on basis of
in vivo data (9). The discrepancy between in vivo and in vitro
estimates might be explained by a role of active metabolites
(25). Although their concentrations in plasma are 10–1000 times
lower compared to remoxipride (25), four metabolites
(FLA797, FLA908, NCQ436, NCQ469) showed 2–200 times
higher in vitro afﬁnity for the D2 receptor than the parent
remoxipride (33). Moreover, these metabolites showed in vivo
activity on DOPA accumulation in rat striatum (35). Interest-
ingly, this could be an alternative explanation of the two-phasic
decline of prolactin (Fig. 2b). In that case, the PRL response
would be the consequence of D2 receptor binding of both
remoxipride and its active metabolites. Since the PK proﬁle of
the active metabolite lags behind that of remoxipride (25), the
ﬁrst part of the PRL response would be explained by
remoxipride effect, whereas the second part would be driven
by the active metabolites. Nevertheless, the contribution of
activemetabolites to the in vivo remoxipride potency is tentative
and in further research remoxipride should be analyzed in
conjunction with its active metabolites to obtain a complete
picture of its PK/PD characteristics.
ACTH as a Biomarker of Adrenergic Receptor Antagonism
To the knowledge of the authors, no studies have been
performed for the ACTH response upon remoxipride, but
other dopaminergic agents have been investigated. The
relation between dopaminergic agents and ACTH is rather
intriguing. Although the dopamine D2 agonist bromocriptine
is used to treat ACTH hypersecretion (14), suggesting an
inhibiting effect, this appears to be speciﬁc for tumor cells
(36). On the contrary, ACTH release in rats was stimulated
by the dopamine D2 agonists quinpirole and apomorphine, as
well as by the dopamine reuptake inhibitor GBR12909. These
effects were blocked by the dopamine D2 antagonists
haloperidol and sulpiride suggesting a D2-speciﬁc response
(37,38). However, counterintuitively, haloperidol could also
stimulate ACTH release (39,40), which was also observed for
the D2 antagonists thioproperazine (41) and eticlopride (42).
Yet, sulpiride did not stimulate ACTH release (37).
Since the stimulatory effect of D2 agonists on ACTH
release has been conﬁrmed to be D2 speciﬁc, it is likely that
the effect of the D2 antagonists is an off-target effect that
these drugs have in common.
Although 5-HT1A agonists can induce ACTH release
(43), remoxipride and haloperidol have no afﬁnity for the 5-
HT1 receptors (34). Moreover, 5-HT1A agonists are known to
stimulate GH release (43), which was not observed for
remoxipride in the present study. On the other hand, the
in vitro afﬁnity to adrenergic receptors of both remoxipride
(to α2 receptor) and haloperidol (to α1 receptor) was only
10–50 times lower than to dopamine D2 receptors (34,44).
Maximal ECF remoxipride concentrations that were ob-
served in rats receiving 14.0 mg/kg (1.3–3.1 μM) exceed the
EC50,prl (0.064 μM) by 20–50 times. In contrast, sulpiride has
negligible afﬁnity to adrenergic receptors (at least 100 times
lower than its afﬁnity to D2 receptor) (34,44). In addition,
haloperidol showed considerable in vivo receptor occupancy
and functional activity at central adrenergic receptors (45,46).
The endogenous ligands for adrenergic receptors are epi-
nephrine and norepinephrine, which are known to inhibit the
release of corticotropin releasing hormone (CRH) from the
hypothalamus to the pituitary (47). In the pituitary, CRH
stimulates the release of ACTH from the corticotrophs, which
was found to be the pathway for thioproperazine to stimulate
ACTH release (41). This is in line with our observation that
ACTH release is likely to be linked to remoxipride in
brainECF, suggesting a drug–receptor interaction at the
hypothalamus level. Following these observations, it is thus
well possible that the effect of remoxipride on ACTH is
elicited via antagonism of the centrally located adrenergic
receptor, leading to an increased release of CRH and ACTH.
PK/PD Model for ACTH
The mechanism of ACTH being released upon remoxipride
administration thus seems similar to that of PRL, albeit via
another pathway. Whereas PRL is released from lactotrophs,
stimulated by reduction of dopamine, ACTH is secreted from
corticotrophs, stimulated by induction of CRH. This provides
further evidence for our observation that a pool model described
the ACTH response (Table III). Furthermore, as discussed
above, ACTH is suggested as a biomarker for an adrenergic
response. Although it was not possible to determine the exact
EC50,ACTH (2.61 μM), since it was dependent on the Emax,ACTH
that was ﬁxed to an arbitrary value of at least 10, we can conclude
that it is at least 40 times higher than EC50,prl (0.064 μM). This
conﬁrms the earlier suggestion that ACTH represents an off-
target effect of remoxipride, possibly via the adrenergic receptor.
Thus, by simultaneous analysis of eight hormones in
plasma for a multi-biomarker approach, we could identify
ACTH as additional biomarker for remoxipride in rats.
Together with PRL, this biomarker provides insights into
the effects of remoxipride on the neuroendocrine system
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through different pathways. However, whereas animals in
preclinical experiments are very similar, having the same
genetic background and environmental conditions, humans
are highly heterogeneous in terms of genetic background,
lifestyle, disease, age, and other factors that may inﬂuence
drug efﬁcacy (48). Such variation may impact the response of
the neuroendocrine system to D2 antagonists. For example,
corticotrophs in pituitary tumors have higher D2 receptor
expression and become sensitive to dopamine D2 agents (36),
which would impact the ACTH response, but not the PRL
response. Thus, taking into account a multi-biomarker would
give more precise insights in the PK/PD processes on an
individual level, providing opportunities for personalized
medicine.
Furthermore, as discussed above, the D2 antagonists
haloperidol (40), thioproperazine (41), eticlopride (42), and
remoxipride all stimulate ACTH release, whereas sulpiride
(37) does not show such response. With PRL only, it is shown
that some D2 antagonists cause hyperprolactinemia, but
others not, providing a sub-classiﬁcation of D2 antagonists.
A multi-biomarker provides further sub-classiﬁcation, for
example distinguishing sulpiride from haloperidol,
thioproperazine, eticlopride, and remoxipride. Thus, our
approach enables detailed sub-classiﬁcation and provides
comprehensive insights in differential effects among drugs.
As such, the approach should ultimately be applied to a series
of dopamine D2 antagonists and agonists.
Finally, since now, we could reveal the neuroendocrine
response by combining a multi-biomarker discovery approach
with PK/PD modeling, we have provided a conceptual basis
to use for example metabolism for a multi-biomarker
paradigm. This is expected to provide a much more extensive
multi-biomarker than the biomarkers used in the current
study. With the metabolomics technique, more than 100
endogenous metabolites can be measured, providing a
promising next step with an untargeted biomarker discovery
approach rather than the relatively targeted approach
exploited in our study. These metabolite responses are then
analyzed by multivariate statistics (49), which would identify
the underlying shared responses among the metabolites and
provide a multi-biomarker. Metabolomics has been success-
fully applied for identiﬁcation of new biomarkers of drug
effects (2–4), although no studies have been performed that
combined it with PK/PD modeling. Therefore, further studies
should expand on the current study by using metabolomics
for untargeted biomarker discovery.
In conclusion, often multi-biomarker discovery and PK/
PD modeling are separated ﬁelds, limiting the insights that
can be obtained in in vivo pharmacological studies. In our
study, we overcame this limitation by combining these ﬁelds,
revealing remoxipride effects not only on PRL, but also
ACTH. Moreover, using PK/PD modeling, we revealed that
both hormone responses were (i) likely to be driven by
remoxipride in brainECF and (ii) described by a pool model
according to the underlying physiology of hormone release
from Btroph^ cells. With that, we quantiﬁed the dose response
over a large dose range, enabling the prediction of neuroen-
docrine responses after different doses of remoxipride. More
generally speaking, our study shows how multi-biomarker
discovery can reveal and PK/PD modeling can quantify the
multiple neuroendocrine responses for single drug action.
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